PATENT CLAIM ANALYSIS

Application Number: 16103328
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "051000"]

Abstract:
Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Claim (Index 7):
The method according to  claim 1 , wherein diquafosol or a salt thereof is at a concentration of 3% (w/v) in the ophthalmic solution.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 2.0597
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14386169', '15289273', '15539283', '14717073', '13821717']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7625737710820972
- 35 USC 102 Novelty (BERT): 0.602636803348888
- Combined Prediction Score: 0.7465800743087764
- Mean Citation Score: 366.176888
- Max Citation Score: 498.72366
- Similarity Product: 483.7829809249412

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test